Search clinical trials for: AG-221

Total 1879 results

Addpharma Inc.

Completed

A Study to Evaluate the Safety and Pharmacokinetics of AD-221 Compared to Coadministration of AD-221A and AD-221B

Hyperlipidemias

Korea, Republic of
Celgene

Completed

Radiolabeled Study of AG-221 in Healthy Male Subjects.

Healthy Volunteers
Celgene

Completed

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

Healthy

United States
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Groupe Francophone des Myelodysplasies

Active, not recruiting

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia Acute Myeloid

France
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States
Celgene
Agios Pharmaceuticals, Inc.

Completed

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Hematologic Neoplasms

United States, France
Celgene
Celgene Corporation

Completed

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Glioma | Solid Tumor | Angioimmunoblastic T-cell Lymphoma | Chondrosarcoma | Intrahepatic Cholangiocarcinoma

United States, France
Stanford University
Celgene Corporation

Recruiting

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Leukemia | Leukemia, Myeloid | Monocytic Leukemia

United States
Celgene

No longer available

Expanded Access for AG-221

Acute Myeloid Leukemia

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Australia, Austria, Belgium, Estonia, Finland, France, Germany, Ireland, Lithuania, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland
Addpharma Inc.

Completed

A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A

Primary Hypercholesterolemia

Korea, Republic of
Celgene

Active, not recruiting

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Leukemia, Myeloid, Acute

United States, France, Italy, Korea, Republic of, Spain, United Kingdom, Australia, Canada, Germany, Netherlands, Portugal, Switzerland, Belgium, Sweden
Roswell Park Cancer Institute
Celgene

Withdrawn

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | IDH2 Gene Mutation | Blasts Under 5 Percent of Peripheral Blood White Cells | Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level

United States
Vedic Lifesciences Pvt. Ltd.
Enovate Biolife Pvt Ltd

Completed

A Study to Evaluate Efficacy of IP on Alertness and Mental Fatigue (ALERMEN)

Mental Fatigue

India
Agios Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

Healthy Volunteers

United States
Molnlycke Health Care AB

Completed

Evaluating the Efficacy of an Absorbent Foam Dressing Containing Silver (Mepilex Ag) Versus the Same Dressing Without Silver Used on Subjects With Venous Leg Ulcers or Mixed Ulcers

Venous Leg Ulcers | Mixed Leg Ulcers

France, Germany, Netherlands, Czech Republic
Agios Pharmaceuticals, Inc.

Completed

A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C] AG-881 and Concomitant Intravenous Microdose of [13C315N3] AG-881

Healthy Male Participants

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Healthy Volunteers | Anemia, Sickle Cell

United States, Spain, Denmark
MediciNova

Completed

Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Agios Pharmaceuticals, Inc.

Completed

Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults

Healthy Volunteers

United States
Therapex Co., Ltd

Not yet recruiting

A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Carcinoma, Non-Small-Cell Lung | EGFR Mutant Advanced Non-Small Cell Lung Cancer
Joint Authority for Päijät-Häme Social and Health...

Recruiting

Recognition and Treatment of Dysglycemia. AGS - Acute Glucose Service (AGS)

Arthroplasty Complications | Dysglycemia

Finland
Agios Pharmaceuticals, Inc.

Terminated

A Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Lymphoma

United States
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy Volunteers

Chronic Spontaneous Urticaria
Agios Pharmaceuticals, Inc.

Completed

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

Healthy Volunteers

United States
Agios Pharmaceuticals, Inc.

Completed

Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin

Healthy | Japanese | Non-Asian

United States
Ahn-Gook Pharmaceuticals Co.,Ltd
Hanyang University; Ewha Womans University; Konkuk University Medical Center; Kyunghee... and other collaborators

Completed

Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "AG NPP709 Syrup"

Bronchitis | Acute Upper Respiratory Tract Infections

Korea, Republic of
Pfizer

Terminated

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

Age-Related Macular Degeneration

United States, United Kingdom, Australia, Netherlands
Icosavax, Inc.

Completed

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

Healthy

United States
Azienda Ospedaliera Universitaria Mater Domini,...
Associazione Italiana per la Ricerca sul Cancro

Completed

A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment (LNA-i-miR221)

Advanced Solid Tumor | Hepatocarcinoma | Multiple Myeloma, Refractory

Italy
Molnlycke Health Care AB

Recruiting

Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns

Partial-thickness Burn

United States
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Myelodysplastic Syndromes

Israel, United States, Korea, Republic of, Australia, France, Germany, Spain, United Kingdom, Czechia, Austria, Italy, Greece, Poland
Coloplast A/S

Completed

Biatain Ag vs Biatain in the Treament of Leg Ulcers

Leg Ulcers
MediciNova

Completed

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

Asthma

United States
Brigham and Women's Hospital
Medline Industries

Completed

Evaluation of Opticell Ag on Split-Thickness Skin Graft Donor Sites in Adult Subjects (STSG)

Split-thickness Skin Graft Donor Sites
Karl Landsteiner University of Health Sciences
Ludwig Boltzmann Gesellschaft

Not yet recruiting

The Effectiveness of a Serious Game Targeting Interpersonal Emotion Regulation in Early Adolescents

Interpersonal Relations
The University of Texas Medical Branch, Galveston

Withdrawn

PermeaDerm® vs. Mepilex-Ag® in Promoting Healing of Partial-thickness Burn Wounds

Partial-thickness Burn

United States
University of Wisconsin, Madison

Terminated

BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19)

COVID-19 | SARS-CoV2 Infection

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

Acute Myeloid Leukemia

United States
Second Affiliated Hospital of Wenzhou Medical University

Completed

Clinical Value of the MRI Combined With SCC-Ag for the Diagnosis of HSIL (CIN 2/3)

Magnetic Resonance Imaging Examination

China
Agios Pharmaceuticals, Inc.

Completed

A Phase I Study of AG-348 in Healthy Volunteers (AG-348MAD)

Healthy Volunteer

United States
MediciNova

Completed

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

Asthma

United States
Molnlycke Health Care AB

Completed

A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients. (MpTAg03)

Burn Injury | Skin Graft

United States
Stedical Scientific, Inc.

Recruiting

Evaluation of the Effectiveness of PermeaDerm® (PD) as Compared to Mepilex Ag®

Thermal Burn

United States
Institut de Recherches Internationales Servier

Completed

A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function

Hepatic Impairment

United States
Servier
Servier Pharmaceuticals, LLC

Available

Vorasidenib Expanded Access Program

Pathologic Processes | Glioma | Neoplasms | Neoplasms by Histologic Type | Neoplasms, Glandular and Epithelial | Recurrence | Disease Attributes | Neoplasms, Germ Cell and Embryonal | Neoplasms, Neuroepithelial | Neuroectodermal Tumors | Neoplasms, Nerve Tissue
University of Florida
Hospital Santo Tomas

Withdrawn

Additive Benefit of the Urine LAM Test to Current TB Diagnostics in HIV Positive Adults in Panama City, Panama

HIV | Tuberculosis | Histoplasmosis
Molnlycke Health Care AB

Completed

Evaluation of Exufiber Ag+ and Other Gelling Fibre Dressings

Wounds and Injuries

United States
United BioPharma

Completed

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in CSU Patients

Urticaria Chronic

Taiwan

3

Subscribe